Drug companion protocol
Cagrilintide
Also known as: CagriSema (combination)
A long-acting amylin analogue under clinical investigation for weight management, including in combination with semaglutide.
Quickstart Highlights
- Drug class
- Amylin analogue
- Route
- Subcutaneous injection
- Schedule
- Weekly subcutaneous injection
- Evidence score
- 45
Quickstart highlights
- ๐Subcutaneous injection
- ๐ฌAmylin analogue
- ๐Prescription required
How this works
Mechanism of action and pharmacokinetic profile from published data.
Cagrilintide is a long-acting analogue of amylin โ a hormone co-secreted with insulin from pancreatic beta-cells. Amylin slows gastric emptying, suppresses post-meal glucagon secretion, and signals satiety in the brain via area postrema receptors โ a complementary pathway to GLP-1 agonism. Because amylin and GLP-1 work through different pathways, combining cagrilintide with semaglutide (as "CagriSema") may produce additive weight loss beyond either agent alone. Phase 2 data support this hypothesis; Phase 3 trials are ongoing.
- Time to peak (Tmax)
- ~3โ4 days after subcutaneous injection.
- Clearance
- Degraded via proteolytic pathways โ specific clearance data from published Phase 2 trials.
- Elimination half-life
- Approximately 7 days, supporting once-weekly subcutaneous dosing (reported from Phase 1/2 data).
- Bioavailability
- Data from investigational Phase 2 studies; not yet on a product label.
Clinical Benefits & Side Effects
Observed outcomes, adverse effects, and lifecycle considerations from published trial data.
Benefits
Starting in a trial context
Cagrilintide is only available in clinical trials as of 2024โ2025. It has been studied primarily as part of the CagriSema combination (with semaglutide). The dose-escalation protocols vary by trial.
First injection โ taking the first step
This is your first week, and just starting is something to feel good about. You may not notice much physically yet โ that's completely normal at this early, low dose. Some people feel mild nausea or a reduced appetite, while others feel little to nothing different.
Body beginning to adjust to the medication
Your body is still getting used to cagrilintide, and side effects like mild nausea, reduced appetite, or tiredness may come and go. Don't be discouraged if you don't see changes on the scale โ the early weeks are about building a foundation, not dramatic results.
Navigating early side effects with more confidence
By now you may have developed a feel for how your body responds around injection day. Nausea, if present, often peaks within the first day or two after your injection and then eases. Small, frequent meals and staying well hydrated can make a real difference this week.
Completing your first month โ building consistency
Reaching four weeks is a genuine milestone โ consistency now is laying the groundwork for everything ahead. Many people are still in a low-dose adjustment phase and haven't seen major weight changes yet, and that's expected. Focus on locking in good habits around food, hydration, and movement.
Dose may increase โ appetite changes become clearer
If your prescriber has scheduled a dose increase, you may notice appetite suppression becoming more noticeable this week. Some people find they feel satisfied with smaller portions almost without trying โ lean into that, but make sure you're still eating enough nutritious food.
Appetite suppression making meals feel different
Food may feel less urgent or less exciting than it used to โ this is the medication working as intended. It's a good time to focus on eating slowly and mindfully, so you can tune in to your body's genuine hunger and fullness signals. Side effects often start to ease as your body adapts.
Finding a rhythm with food and movement
Many people start to feel more settled this week and find it easier to plan meals and stay active. If nausea has been a challenge in earlier weeks, you may notice it's becoming more manageable. This is a great time to build or strengthen a gentle exercise habit.
Side effects
More frequent in the CagriSema combination than either drug alone
Reported
Reported
Reported; more frequent in combination arm
Lifecycle factors
This is an investigational medicine
Cagrilintide is not commercially available. If you are reading this because you are participating in a trial, all questions about dose, protocol, and tolerability management should go to your trial site team โ not a community forum.
CagriSema GI burden is higher than either drug alone
In Phase 2 data, the combination of cagrilintide and semaglutide produced more GI adverse events than either drug alone, though most were mild-to-moderate. Dose escalation is typically slower to minimise this.
Manage nausea with simple, bland foods
If nausea hits, reach for foods that are gentle on the stomach: plain crackers, dry toast, banana, or plain white rice. Avoid skipping meals entirely when nauseous โ an empty stomach can actually make nausea worse. Cold or room-temperature foods are often better tolerated than hot, strongly-smelling dishes.
Keep a simple weekly log to share with your prescriber
A brief weekly note โ covering your weight, any side effects, energy levels, and how you're eating โ gives your prescriber valuable information to support and adjust your plan. It doesn't need to be detailed: even a note in your phone with a few dot points each week is enough. This log is also a powerful motivator when you look back and see how far you've come.
Important note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. All information presented is based on published clinical trial data. Always follow your prescriber's instructions.
Nutrition & practical guidance
Food, hydration, and adherence tips compiled from trial data and clinical companion content.
Food and hydration
โ Prefer
โ ๏ธ Limit
โ Avoid
Adherence tips
Rotate your injection sites consistently
Inject into the fatty tissue of your abdomen, thigh, or upper arm โ and rotate sites each week to avoid lumps or skin changes at any one spot. Keep a simple note on your phone or a sticky note to track where you injected last. Always follow your prescriber's instructions on exactly how and where to inject.
Let your injection reach room temperature first
Take your cagrilintide out of the fridge **15โ30 minutes before** injecting. A cold injection can sting more and feel uncomfortable going in. Keep it out of direct sunlight while it warms up, and never try to heat it in a microwave or hot water.
Pick a weekly injection day and stick to it
Choosing the same day each week โ for example, every Sunday morning โ makes it much easier to build the habit and reduces the chance of missing a dose. Set a recurring phone reminder with a label like 'Weekly injection day' so it becomes a non-negotiable part of your routine.
Plan lighter meals around your injection day
Many people find that nausea is most noticeable in the 24โ48 hours after their injection. Try to schedule your injection day when you can eat gently โ think plain rice, scrambled eggs, or yoghurt โ rather than on a day with a big social meal or celebration planned.
Protein intake supports the lean mass you want to preserve
Significant weight loss from any GLP-1 class drug can include lean mass loss. Adequate protein (1.2โ1.6 g/kg/day) and resistance exercise help preserve it.
Start every morning with a full glass of water
Before coffee, before scrolling your phone โ drink a full 250โ300 mL glass of water first thing in the morning. This jumpstarts your hydration for the day and can help ease morning nausea. Keep a water bottle visible on your kitchen bench as a prompt.
Sip, don't gulp โ especially when nauseous
Drinking large amounts of fluid quickly can worsen nausea and bloating. Instead, aim to sip water **little and often** throughout the day โ roughly 150โ200 mL every 30โ45 minutes. A marked water bottle or hydration app can help you track this without thinking too hard about it.
Prioritise protein at every meal
When your appetite is reduced, every bite counts โ so make protein the centrepiece of your meals. Aim for at least **20โ30 g of protein per meal** from sources like eggs, Greek yoghurt, tinned fish, legumes, or chicken. Protein helps protect your muscle while your body adjusts, and it keeps you feeling fuller for longer.
Eat smaller portions, more frequently
Rather than three large meals, try **4โ5 smaller meals or snacks** spread across the day. This works with the medication's effect on gastric emptying rather than against it, and reduces the chance of feeling uncomfortably full or nauseous after eating. A small meal might be half a cup of rolled oats with Greek yoghurt, or two boiled eggs on wholegrain toast.
Start with short, low-intensity walks
You don't need to hit the gym hard, especially in the early weeks. A **15โ20 minute walk** after dinner is a great starting point โ it aids digestion, supports blood sugar management, and improves mood. Gradually build toward 30 minutes most days as your energy and comfort allow. Even a stroll around the block counts.
Add light resistance training to protect muscle
As your body loses weight, including some resistance-based movement โ like bodyweight exercises, resistance bands, or light weights โ helps ensure you're maintaining muscle, not just losing it. Aim for **2 sessions per week** of 20โ30 minutes. You don't need a gym; exercises like wall sits, chair squats, and push-ups against a bench are a great start.
Protect your sleep โ it supports your progress
Poor sleep increases hunger hormones and cravings, which can work directly against the appetite-regulating effects of the medication. Aim for **7โ9 hours per night** and try to keep a consistent bedtime. If nausea is disrupting your sleep, speak with your prescriber โ there may be simple strategies that can help.
Measure progress beyond the scales
The number on the scale is just one data point, and it can fluctuate significantly from day to day due to fluid, food, and other factors. Keep a simple weekly note of **non-scale victories**: better energy, improved sleep, walking further without getting puffed, or clothes fitting differently. These are real signs of progress and worth celebrating.
Be patient and compassionate with yourself in early weeks
The first four weeks can genuinely be hard โ nausea, fatigue, and little visible change can feel discouraging. Remember that your body is adjusting to a new medication, and discomfort in these early weeks doesn't mean it isn't working. Reach out to your prescriber or a support person if you're struggling; you don't have to navigate this alone.
Safety and interactions
Share this information with your prescriber for personalised care decisions.
Who should not take this
Cagrilintide is investigational โ not yet approved by the TGA, FDA, MHRA, or EMA. Access is limited to clinical trials. Based on Phase 2 trial exclusion criteria and the amylin receptor class: โข Existing amylin-pathway contraindications are not fully characterised โข Trials have excluded participants with severe GI disease, active eating disorders, severe kidney or liver impairment, recent cardiovascular events, pregnancy, and breastfeeding No formal prescribing label exists. Speak with your trial site or prescriber for any questions about eligibility.
Known interactions
- Insulin and insulin secretagoguessignificant
Amylin analogues can increase hypoglycaemia risk when combined with insulin-stimulating agents.
- GLP-1 receptor agonists (e.g. semaglutide in CagriSema combination)moderate
The CagriSema combination is the primary clinical context for cagrilintide use. GI adverse events were more frequent in combination than either agent alone.
- Oral medicines with narrow therapeutic indexmoderate
Additive gastric-emptying slowing from amylin + GLP-1 dual mechanisms may alter absorption of orally administered drugs.
Storage and handling
As an investigational biologic, storage specifics are governed by the trial protocol or supplying pharmacy. Amylin analogues in this class are expected to require refrigeration at 2โ8ยฐC (36โ46ยฐF). Freezing typically destroys peptide biologics. Always follow the storage instructions provided by your trial site.
Research evidence
Published studies connected to this peptide with dosage and outcomes context.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide 4.5 mg with semaglutide 2.4 mg (CagriSema) in adults with overweight or obesity: a randomised, controlled, phase 1b trial
Human trial ยท 2021 ยท The Lancet ยท n=96 ยท Adults with overweight or obesity (BMI 27โ39.9) without type 2 diabetes
96 adults were randomised to once-weekly cagrilintide 4.5 mg alone, semaglutide 2.4 mg alone, CagriSema combination, or placebo for 20 weeks. Mean body-weight change was โ15.6% with CagriSema versus โ8.8% with semaglutide alone and โ8.7% with cagrilintide alone โ suggesting additive effects of the combination.
Reported outcomes
- weight_loss: Additive weight loss suggests complementary mechanisms โ amylin and GLP-1 pathways appear to act synergistically. (Secondary)
- weight_loss: Mean body-weight change of โ15.6% with CagriSema versus โ8.8% with semaglutide alone and โ8.7% with cagrilintide alone at 20 weeks. (Primary outcome)
Reported dosage
- 4.5 mg ยท once weekly subcutaneous ยท 20 weeks โ Combined with semaglutide 2.4 mg in the CagriSema arm of the Phase 1b trial.
Get the full companion experience in Viora
Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.
Available on iOS and Android.